Clinical trials: Positron-Emission Tomography
Coronary Artery Disease
A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
The primary objective of the study is to assess the diagnostic efficacy (specificity and sensitivity) of flurpiridaz F18 injection PET myocardial perfusion imaging (MPI) compared to single photon emission computed tomography…
- Trial name
- NCT01347710
- Testing
- Flurpiridaz F18, 99mTechnicium (sestamibi or tetrofosmin)
- Where
- 81 sites in United States, Canada and 2 more
- Volunteers
- 795 people
- Sponsor
- Lantheus Medical Imaging
Colorectal Cancer
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
The purpose of this study was to determine the activity of two doses of robatumumab (SCH 717454, MK-7454) in participants with relapsed or recurrent colorectal cancer.
- Trial name
- NCT00551213
- Testing
- Robatumumab, Irinotecan, Cetuximab
- Volunteers
- 67 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastro-Enteropancreatic Neuroendocrine Tumor
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
The purpose of this clinical research is to confirm the optimal dose of 68Ga-satoreotide trizoxetan (68Ga-IPN01070), formerly 68Ga-OPS202, as a PET imaging agent to be used to detect and localize gastro-entero-pancreatic…
- Trial name
- NCT03220217
- Testing
- Satoreotide trizoxetan 5-20μg, Satoreotide trizoxetan 30-45μg
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 29 people
- Sponsor
- Ipsen
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
PET Scan and CT Scan in Evaluating Response in Patients Undergoing Radiofrequency Ablation for Lung Metastases
RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Diagnostic procedures, such as PET scan and CT scan, may help doctors measure the patient's response to treatment.
- Trial name
- TEPARF (NCT00382252)
- Testing
- computed tomography, positron emission tomography, radiofrequency ablation
- Where
- 3 sites in France
- Volunteers
- 89 people
- Sponsor
- Institut Bergonié
Healthy Participants
Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51
This is a phase 1, open-label, positron emission tomography (PET) study in healthy adult participants to determine the relationship between plasma concentration and brain target occupancy of ASN51 following a single oral dose.
- Trial name
- NCT06390098
- Testing
- ASN51
- Where
- United Kingdom
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Asceneuron S.A.
Liver Cancer, Liver Neoplasm
Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
Background: Treatment for liver cancer can include surgery, transplant, and chemotherapy. It can also include other minimally invasive tumor treatments such as transarterial chemoembolization (TACE).
- Conditions
- Liver Cancer, Liver Neoplasm, Hepatocellular Carcinoma, HCC
- Trial name
- NCT02471313
- Testing
- [18F] FMISO
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Lymphoma
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine, dacarbazine, cyclophosphamide, etoposide, procarbazine hydrochloride, vincristine sulfate, and prednisone, work in…
- Trial name
- NCT01390584
- Testing
- Doxorubicin, Bleomycin, Vinblastine
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Alzheimer Disease
A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers
A preliminary study to test how florbetapir F 18 (18F-AV-45) acts in the brains and bodies of healthy elderly people and patients with Alzheimer's Disease (AD) by using a positron emission tomography (PET) scanner.
- Trial name
- NCT01565291
- Testing
- florbetapir F 18
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Mild Cognitive Impairment
Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI
To investigate whether [18F]NAV4694 positron emission tomography (PET) scan findings have the ability to distinguish subjects with mild cognitive impairment (MCI) who progress to Alzheimer's disease (AD) from those who do not.
- Trial name
- NAV4-04 (NCT01812213)
- Testing
- [18F]NAV4694
- Where
- 11 sites in United States
- Volunteers
- 76 people
- Sponsor
- Navidea Biopharmaceuticals
Prostate Cancer
Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence
The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy…
- Trial name
- NCT03353740
- Testing
- Ga-68 labeled PSMA-11 PET
- Where
- United States
- Volunteers
- 346 people
- Sponsor
- Thomas Hope
Alzheimer's Disease
Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)
The intent of this research protocol is to test the equivalency of two amyloid imaging drugs (C11 Pittsburgh Compound B and F18 Flutemetamol).
- Trial name
- NCT01607476
- Testing
- C11 PiB, F18 Flutametamol
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Mild Cognitive Impairment, Alzheimer's Disease
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically…
- Trial name
- NCT01028053
- Testing
- Flutemetamol (18F) Injection
- Where
- United States
- Volunteers
- 365 people
- Sponsor
- GE Healthcare
Intravenous Infiltration
Patterns and Prevalence of FDG Extravasation in PET/CT Scans
PET (Positron Emission Tomography) images are used to help make patient management decisions in staging and treatment assessment, often after a cancer diagnosis.
- Trial name
- Lucerno device (NCT03041090)
- Testing
- Lucerno ID (identification) System
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- St. Louis University
Carotid Artery Disease, Carotid Stenosis
TRACER RGD-K5 Carotid Plaque Imaging Study
The purpose of this study is to investigate the ability of the compound[F-18]RGD-K5, when used as a tracer during PET (positron emission tomography) imaging, to detect regions of unstable atherosclerotic plaque in the carotid…
- Trial name
- TRACER (NCT01968226)
- Testing
- [F-18] RDG-K5
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- The Cleveland Clinic
Non-small Cell Lung Cancer
Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer
The primary objective of this study is to evaluate patient-reported outcomes during and after concurrent chemoradiotherapy for locally-advanced non-small cell lung cancer.
- Trial name
- REPAINT (NCT03481114)
- Testing
- PET-based, dose-painted, accelerated chemoradiotherapy, Standard chemoradiotherapy
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Albert Einstein College of Medicine
Prostatic Neoplasms, Prostate Cancer
NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
The purpose of this study is to assess whether NaF PET/CT scans can be used to evaluate treatment response in bone metastases in subjects with prostate cancer treated with the investigational drug, TAK-700.
- Trial name
- NCT01816048
- Testing
- TAK-700, Fluorine F 18 Sodium Fluoride, Positron Emission Tomography
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Wisconsin, Madison
Lung Cancer, Metastatic Cancer
Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: A positron emission tomography scan is a procedure in which a small amount of radioactive sugar is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where…
- Trial name
- NCT00559897
- Testing
- 3'-deoxy-3'-[18F]FLT, Single photon emission computed tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Brain Cancer, Glioma
Image-Guided Stereotactic Biopsy of High Grade Gliomas
The purpose of this study is to evaluate high and low areas of growth, or proliferation, within the tumor. An imaging technique using a very small amount of a radioactive tracer called 18Ffluoro-deoxy-L-thymidine (18F-FLT) can…
- Trial name
- NCT00979810
- Testing
- 18F-FLT PET Scan
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Alzheimer's Disease
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
This study in individuals with early Alzheimer's disease is designed to assess:(1) safety and tolerability (2) the capacity of ACC-001 and QS-21 adjuvant to reduce brain amyloid load as measured by positron emission tomography…
- Trial name
- NCT01227564
- Testing
- ACC-001 3 μg/ QS-21 50 μg, ACC-001 10 μg/ QS-21 50 μg
- Where
- 40 sites in United States
- Volunteers
- 63 people
- Sponsor
- Pfizer
Alzheimer's Disease
18F-AV-1451 High Resolution Autopsy Study
The study is designed to examine the relationship between imaging results detected on a 18F-AV-1451 PET scan and pathology found at autopsy within six months of imaging.
- Trial name
- NCT02350634
- Testing
- Flortaucipir F18
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Avid Radiopharmaceuticals